Mitsutomi Ishiyama1, Todd Richards1, Upendra Parvathaneni2, Yoshimi Anzai3. 1. Department of Radiology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195. 2. Department of Radiation Oncology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195. 3. Department of Radiology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195. Electronic address: anzai@uw.edu.
Abstract
PURPOSE: To determine if dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) parameters such as permeability surface area (PS) and blood volume (BV) allow differentiating between new head and neck (HN) cancer, recurrent HN cancer, and post-treatment benign changes. METHOD: A total of 35 patients with newly diagnosed, recurrent, and benign post-treatment benign changes underwent DCE-MRI. PS and BV were calculated. RESULTS: PS values of the lesion were 2.3×10(4)±5.8×10(4) for the newly diagnosed cancer group, 3.3×10(4)±1.7×10(4) for the recurrent cancer group, and 4.8×10(4)±8.1×10(4) for the post-treatment benign change group (P=.031). CONCLUSION: Post-treatment benign changes in the HN region had significantly high permeability property than newly diagnosed or previously treated recurrent tumor.
PURPOSE: To determine if dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) parameters such as permeability surface area (PS) and blood volume (BV) allow differentiating between new head and neck (HN) cancer, recurrent HN cancer, and post-treatment benign changes. METHOD: A total of 35 patients with newly diagnosed, recurrent, and benign post-treatment benign changes underwent DCE-MRI. PS and BV were calculated. RESULTS: PS values of the lesion were 2.3×10(4)±5.8×10(4) for the newly diagnosed cancer group, 3.3×10(4)±1.7×10(4) for the recurrent cancer group, and 4.8×10(4)±8.1×10(4) for the post-treatment benign change group (P=.031). CONCLUSION: Post-treatment benign changes in the HN region had significantly high permeability property than newly diagnosed or previously treated recurrent tumor.
Authors: J Y Lee; K L Cheng; J H Lee; Y J Choi; H W Kim; Y S Sung; S R Chung; K H Ryu; M S Chung; S Y Kim; S-W Lee; J H Baek Journal: AJNR Am J Neuroradiol Date: 2019-07-18 Impact factor: 3.825